Literature DB >> 22555404

Anti-phosphatidylserine, anti-cardiolipin, anti-β2 glycoprotein I and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestational weeks.

Mai S Sater1, Ramzi R Finan, Farah M Abu-Hijleh, Tala M Abu-Hijleh, Wassim Y Almawi.   

Abstract

OBJECTIVE: To investigate the association of antibodies to β2-glycoprotein I (anti-β2GPI), cardiolipin (ACA), phosphatidylserine (anti-PS) and prothrombin (anti-PT) with recurrent spontaneous miscarriage (RSM). STUDY
DESIGN: Case-control study involving 277 RSM cases and 288 controls: autoantibody levels were measured by ELISA. Differences between cases and controls were analyzed by nonparametric Mann-Whitney test, and logistic regression was used in analyzing the association of autoantibodies with RSM.
RESULTS: Anti-PS IgG, ACA IgM and IgG, and anti-PT IgM were significantly associated with RSM risk, and differential antibody association was noted according to BMI and primary and secondary RSM. Higher prevalence of elevated anti-PS IgG was seen in cases, with the strongest risk above the 99th percentile. For ACA IgM, 28 cases (10.1%) and 5 controls (1.7%) were positive, with increasing OR for increasing cut-off points, which was significant at antibody titers >99th percentile. For ACA IgG, 101 cases (36.5%) and 13 controls (4.5%) were positive, with graded increase in OR for increasing cut-off points, which was significant at titers >90th percentile (maximal at titers >99th percentile). For anti-PT, 23 cases (12.0%) and 9 controls (6.1%) were positive, with increased OR at titers >90th percentile. Regression analyses confirmed the independent association of anti-PS IgG, ACA IgM and IgG with RSM, and significant RSM risk was associated with high anti-PS IgG (P<0.001) and ACA IgM (P<0.001) titers, and a dose-dependent increase in RSM risk was seen with progressively increased ACA IgG titers. No significant association existed between anti-PT IgM and RSM.
CONCLUSION: Elevated ACA IgM and IgG, and anti-PS IgG antibodies are positively associated with RSM.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555404     DOI: 10.1016/j.ejogrb.2012.04.001

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  A Study of Anti Beta-2 Glycoprotein I and Anti-Prothrombin Antibodies in Patients with Unexplained Recurrent Pregnancy Losses.

Authors:  Angad Singh; Anita Nangia; Sunita Sharma; Manju Puri
Journal:  Indian J Hematol Blood Transfus       Date:  2015-04-03       Impact factor: 0.900

2.  Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin.

Authors:  Amaris Castanon; Grant Pierre; Rohan Willis; E Nigel Harris; Elizabeth Papalardo; Zurina Romay-Penabad; Alvaro Schleh; Praveen Jajoria; Monica Smikle; Karel DeCeulaer; Anne Tebo; Troy Jaskowski; Marta M Guerra; D Ware Branch; Jane E Salmon; Michelle Petri; Emilio B Gonzalez
Journal:  Am J Clin Pathol       Date:  2018-03-29       Impact factor: 2.493

3.  Increased Performances of the Biological Diagnosis of the Antiphospholipid Syndrome by the Use of a Multiplex Assay.

Authors:  M Sénant; H Rostane; F Fernani-Oukil; F Hosking; F Bellery; A Courchinoux; E Tartour; L Darnige; M-A Dragon-Durey
Journal:  J Immunol Res       Date:  2015-05-06       Impact factor: 4.818

4.  Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes.

Authors:  Polona Žigon; Katja Perdan Pirkmajer; Matija Tomšič; Tanja Kveder; Borut Božič; Snežna Sodin Šemrl; Saša Čučnik; Aleš Ambrožič
Journal:  J Immunol Res       Date:  2015-05-20       Impact factor: 4.818

Review 5.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.